Dear Editors,

Kanis et al. erroneously state in a recent paper about the diagnosis and management of osteoporosis in postmenopausal women that 100 μg of PTH(1-84) is equivalent to 40 μg of teriparatide, PTH(1-34) \[[@CR1]\]. This equivalence was calculated from their respective molecular weights (4,115 for teriparatide \[[@CR2]\], 9,426 for full-length PTH \[[@CR3]\]) but does not consider bioavailability. The bioavailability of PTH(1-34) and PTH(1-84) are 95% and 55%, respectively \[[@CR4], [@CR5]\].

Bioequivalence requires that the number of PTH(1-34) and PTH(1-84) molecules should be the same: *N*~PTH(1-34)~ = *N*~PTH(1-84)~

The clinical dose is based on molecular weight and bioavailability leading to the equation: $$\documentclass[12pt]{minimal}
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\begin{document}$$\begin{array}{*{20}l}{\frac{{m_{{\text{PTH}}\left( {{\text{1 - 34}}} \right)} \times P_{{\text{abs}}\left( {{\text{1 - 34}}} \right)} }}{{M_{{\text{PTH}}\left( {{\text{1 - 34}}} \right)} }} = } \hfill & {\frac{{m_{{\text{PTH}}\left( {{\text{1 - 84}}} \right)} \times P_{{\text{abs}}\left( {{\text{1 - 84}}} \right)} }}{{M_{{\text{PTH}}\left( {{\text{1 - 84}}} \right)} }}} \hfill \\\end{array} $$\end{document}$$(where *M* is the molecular weight of PTH, *P*~abs~ the bioavailability, and *m* the mass of PTH).

Using this calculation, 100 µg of PTH(1-84) is equivalent to 25 μg of teriparatide {100 μg × (55/95) × 4,115/9,426 = 25 μg} and these are the approximate doses used in the treatment of postmenopausal osteoporosis.
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